Structures of (A) NTRK1, (B) NTRK2, and (C) NTRK3 with the locations of the missense mutations in hematologic malignancies (studied in this report), missense mutations in solid tumors, and the common tyrosine kinase domain resistance mutations. (Adapted from Joshi SK, Qian K, Bisson WH, et al. Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms. Blood. 2020;135:2159-2170, Suppl Figure 3.)